Ozempic Goes Global
Richardson Dackam@richardsondx
+1.4%
since Oct 1
The idea
I believe GLP-1 weight-loss drugs are just getting started globally, with obesity rates far outpacing current usage, and that Novo Nordisk captures the largest share because "Ozempic" has become the generic word for the category, the way Frigidaire did for refrigerators. Novo sits at the maximum single-position size, so the rest spreads across the manufacturers, syringe and pen makers, distributors, a smaller Lilly stake as insurance, next-wave drugmakers, and generic producers carrying semaglutide into emerging markets.
What it owns
- It makes Ozempic, the drug that has become synonymous with weight loss globally, positioning it to capture the largest share of the expanding GLP-1 market as these treatments reach new countries. · Novo NordiskIt developed Ozempic, which has become the colloquial term for weight-loss drugs, giving it significant brand recognition and market share in the rapidly growing GLP-1 category, particularly in emerging markets like India where it has already adjusted pricing to maintain its competitive position.25%
- These companies manufacture the syringes, cartridges, pen needles and other components that injectable GLP-1 drugs require, earning revenue tied to prescription volume rather than which brand prevails. · West Pharmaceutical ServicesIt makes the components inside injector pens and vials, generating revenue proportional to GLP-1 injection volumes rather than dependent on any single drugmaker's market position., Thermo Fisher ScientificIt provides contract manufacturing capacity for pharmaceutical production, capturing growth as demand for GLP-1 doses scales from niche to mass market., Becton DickinsonIt manufactures pen needles by the billions, earning revenue from injection volume growth that does not depend on which GLP-1 brand patients use., Stevanato GroupIt produces syringes and cartridges for injectable drugs and supplies directly to major GLP-1 makers, benefiting from global demand expansion in the category.22%
- These companies are developing obesity drugs with different mechanisms or dosing schedules, offering exposure to the category's expansion while betting on enough market size to support multiple competitors. · AstraZenecaIt is developing an oral GLP-1 candidate, which matters for global markets where pills are cheaper to manufacture and distribute than refrigerated injectable pens., AmgenIts obesity candidate MariTide could dose monthly rather than weekly, positioning it to win share if the market grows large enough to sustain multiple treatments., Viking TherapeuticsIt is developing obesity drug candidates with strong early trial results, offering concentrated exposure to the next-generation treatments that could capture market share from existing GLP-1s., PfizerIt acquired its obesity programs rather than developing them internally, placing it in the pool of competitors contending for share of a larger global market., Structure TherapeuticsIt is developing an oral GLP-1 pill for markets where oral formulations are cheaper to produce and easier to distribute than injectable pens.18%
- These distributors move the majority of prescriptions through the US healthcare system, so their revenue grows alongside GLP-1 prescription counts regardless of which drugmaker's product flows through their supply chain. · McKessonIt distributes a large share of US prescriptions, so its revenue grows as GLP-1 scripts expand across the healthcare system., CencoraIt is a major US pharmaceutical distributor whose revenue scales with the volume of GLP-1 prescriptions flowing through its logistics network.10%
- It develops GLP-1 drugs including oral formulations, offering protection if clinical efficacy and alternative dosing forms outweigh brand recognition in determining market winners. · Eli LillyIts GLP-1 pipeline includes oral formulations that could compete on efficacy and convenience, making it valuable protection if drug performance matters more than brand recognition.9%
- These generic manufacturers will carry semaglutide to emerging markets once patents expire, capturing the opportunity to serve price-sensitive populations where the vast majority of future patients live. · Dr. Reddy's LaboratoriesIt will launch semaglutide generics in emerging markets once patents expire, serving the price-sensitive populations where the largest opportunity for GLP-1 volume growth exists., Teva PharmaceuticalIt is a generic semaglutide manufacturer that will reach price-sensitive emerging markets where patent expirations unlock access for billions of potential patients.9%
- Cash7%